Company intelligence / Profile preview
Domain Therapeutics
Illkirch-Strasbourg, Francedomaintherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Domain Therapeutics is advancing multiple programs targeting GPCRs, with its lead candidate DT-9081 (EP4R antagonist) in Phase 1 clinical trials for solid tumors. Other programs include DT-7012 (anti-CCR8 antibody) and DT-9046 (biased antagonist of PAR2) in preclinical development.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesAntibodies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
PfizerMerck KGaA
Beyond the preview
Go deeper on Domain Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Domain Therapeutics.